PatientsVille.com Logo


Novoplatinum Medical Research Studies

Up-to-date List of Novoplatinum Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Novoplatinum Medical Research Studies

Rank Status Study
1 Recruiting Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: carboplatin
Outcome Measures: To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.;   Determine the rate of successful planned treatment completion of carboplatin in each group;   Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.;   Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent.
2 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
Outcome Measures: Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 2);   Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 3);   Investigator-determined Overall Response Rate (ORR) (Phase 2);   Percentage of subjects who initiated Cycle 6 receiving doublet combination therapy (Phase 2);   Investigator determined Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Safety for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Independent blinded radiologists-determined Overall Response Rate (ORR) (Phase 3);   Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Compare disease control rate for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Duration of Response for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Safety of each treatment regimen for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Investigator assessed Progression Free Survival (PFS)for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Incidence of subjects experiencing dose modifications (dose interruptions and reductions);;   Percentage of subjects who discontinued from all study treatment adverse event
3 Recruiting Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
Conditions: Carcinoma, Non-Small-Cell Lung;   Urinary Bladder Neoplasms
Intervention: Drug: Carbon-14-labeled carboplatin
Outcome Measures: Correlation of carboplatin-DNA monoadducts induced by microdoses of carboplatin with cancer response to carboplatin-based chemotherapy;   Determination of the underlying chemoresistance mechanisms to carboplatin
4 Recruiting BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
Outcome Measures: To establish the phase II recommended dose of daily oral BKM120;   EXPANSION COHORT:To evaluate the safety and tolerability of daily oral BKM120 (100 mg) + paclitaxel (200 mg/m2) + carboplatin (AUC 6), both given intravenously (IV) on day 1 of a 21-day cycle, with pegfilgrastim support;   To describe the safety of BKM120 combined with paclitaxel and carboplatin,;   To determine the pharmacokinetic profile of daily BKM120.;   To describe and tabulate the radiographic response rate of BKM120 in combination with carboplatin and paclitaxel,;   Correlative Tissue Studies
5 Unknown  Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Condition: Ductal Carcinoma In Situ
Interventions: Drug: Carboplatin i.d. Days 1 & 15;   Drug: Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;   Drug: Normal Saline
Outcome Measures: Compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion;   characterize i.d. carboplatin pharmacokinetics;   characterize clinical extent of disease on MRI and/or mammogram;   characterize the histopathological assessment of DCIS;   Biomarker measurement of Ki-67, TUNEL and G-actin
6 Recruiting Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Conditions: Recurrent Ovarian Cancer;   Platinum Sensitive Ovarian Cancer
Intervention: Drug: Carboplatin
Outcome Measures: To determine the frequency of carboplatin infusion reactions using a slowed carboplatin infusion program;   To characterize the nature and symptoms of carboplatin reactions associated with the slowed infusion protocol.
7 Recruiting Carboplatin Periocular Injection for Retinoblastoma
Condition: Retinoblastoma
Interventions: Drug: carboplatin periocular injection;   Drug: chemotherapy
Outcome Measures: all cause mortality;   side effects of carboplatin periocular injection in the Treatment of Retinoblastoma
8 Recruiting Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Conditions: Central Nervous System Embryonal Tumor;   Germ Cell Tumors
Interventions: Drug: Melphalan;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Filgrastim;   Drug: Pegfilgrastim
Outcome Measures: PHASE I: PRIMARY OBJECTIVE To determine the maximum tolerated dose (MTD) of IA melphalan given with IA carboplatin, osmotic BBBD and delayed IV STS in subjects with recurrent or progressive embryonal and germ cell tumors of the CNS.;   PHASE II: PRIMARY OBJECTIVE To estimate the response rate in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS.;   To describe 2-year progression-free survival (PFS) and overall survival (OS) rates in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS.;   To describe neuropsychological and audiology outcomes in subjects with recurrent or progressive CNS embryonal and germ cell tumors treated with IA carboplatin, IA melphalan, osmotic BBBD and delayed IV STS;   To describe the overall toxicity of IA carboplatin and IA melphalan in conjunction with osmotic BBBD and delayed STS chemoprotection in subjects with recurrent or progressive CNS embryonal or germ cell tumors.
9 Recruiting Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Carboplatin;   Drug: Etoposide;   Procedure: CT Scan;   Procedure: PET Scan;   Genetic: Stem Cell Transplant (STC)
Outcome Measures: Phase I: Maximum-Tolerated Dose of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE);   Phase II: Overall Frequency of Response with Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide;   Phase I: Overall Frequency of Response;   Phase II: Complete Response (CR) and Partial Response (PR) Rate;   Phase II: Progression-Free Survival;   Phase II: Overall Survival;   Phase II: Proportion of Patients Who Are Able to Undergo Stem Cell Transplant (SCT);   Phase II: Safety and Tolerability of the Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide
10 Recruiting Study of Vemurafenib, Carboplatin, and Paclitaxel
Condition: Advanced Cancers
Interventions: Drug: Vemurafenib;   Drug: Carboplatin;   Drug: Paclitaxel
Outcome Measures: Maximum Tolerated Dose (MTD) of Vemurafenib with Carboplatin and Paclitaxel;   Overall Response Rate
11 Recruiting Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: questionnaire administration
Outcome Measures: Progression-free survival (Phase II);   Overall survival (Phase II and III);   Proportion of patients responding to therapy;   Duration of response by treatment;   Overall survival (Phase II);   PFS (Phase III);   Incidence of adverse events as assessed by CTCAE v4 within each arm;   Level of obesity
12 Recruiting Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Drug: dinaciclib;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Recommended phase 2 dose of veliparib/dinaciclib with or without carboplatin determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0);   Pharmacokinetics parameters (maximum concentration [Cmax], area under the curve [AUC], and half-life [t1/2]) of veliparib in the absence or presence of dinaciclib;   Pharmacokinetics parameters (Cmax, AUC, t1/2) of dinaciclib in the presence of veliparib;   Changes in immunohistochemical or biochemical measurements of cyclin-dependent kinase (cdk), poly (ADP-ribose) polymerase 1 activity;   Level of deoxribonucleic acid damage in tissue samples;   Expression of homologous recombination repair proteins;   Anti-tumor activity of veliparib/dinaciclib with or without carboplatin as assessed by Response Evaluation Criteria In Solid Tumors 1.1
13 Recruiting Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: hydrocortisone/placebo;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy
Outcome Measures: MTD of veliparib when given concurrently with standard carboplatin/paclitaxel and radiotherapy, determined according to incidence of dose limiting toxicity (DLT) graded using NCI CTCAE version 4.0 (Phase I);   PFS of patients treated with chemoradiotherapy plus veliparib (Phase II), assessed by RECIST;   Objective response rate, assessed by RECIST (Phase II);   Incidence of serious (>= grade 3) adverse events as measured by NCI CTCAE version 4.0 (Phase II);   PFS (Phase II);   Overall survival (Phase II)
14 Recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
Outcome Measures: Progression-free survival using RECIST v. 1.1;   Overall response rate (partial or complete response) evaluated using the standard RECIST v. 1.1;   Overall survival;   Incidence of severe (grade 3+) adverse events that are classified as either possibly, probably, or definitely related to study treatment, as assessed by NCI CTCAE version 4.0
15 Recruiting Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Conditions: Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: brachytherapy
Outcome Measures: Recurrence-free survival;   Overall survival;   Cumulative incidence of local recurrence;   Cumulative incidence of distant metastases;   Acute and late adverse effects as measured by NCI CTCAE v3.0;   Patient-reported quality of life measured using FACT-G Physical Well-being (PWB) and Functional Well-being (FWB) subscales, FACT-En additional concerns subscale, FACT/GOG-NTX-4 subscale, and items C3 and C5 from the FACT-C
16 Recruiting Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Outcome Measures: To determine the clinical feasibility rate (CFR) of 4 cycles of adjuvant chemotherapy with Pemetrexed and Carboplatin vs. Vinorelbine and Carboplatin;   To determine and compare the drug delivery between both treatment arms;   The relapse free survival;   The overall survival
17 Not yet recruiting Validation of an Adjusted Dosing Algorithm of Carboplatin
Condition: Cancer
Intervention: Drug: Carboplatin
Outcome Measures: to the determine the mean absolute precision error and the mean prediction error of the AUC of carboplatin after dosing carboplatin according to the new dosing algorithm;   Assessment of the incidence and severity of all adverse events that occurred during treatment with carboplatin
18 Recruiting Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: carboplatin;   Procedure: Surgery
Outcome Measures: Establish maximum tolerated dose and define toxicity profile;   Six month progression free survival defined as the proportion of patients with stable disease at 6 months from surgery;   Median progression free survival;   Radiographic response rate;   Overall survival
19 Recruiting A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Condition: Ovarian Cancer
Interventions: Drug: MK-1775;   Drug: Placebo;   Drug: paclitaxel;   Drug: carboplatin
Outcome Measures: Progression-free survival (PFS);   Objective response rate (ORR);   Overall survival (OS)
20 Unknown  Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gemcitabine,Carboplatin,Endostar;   Drug: Gemcitabine(G) Carboplatin(C) Endostar;   Drug: Gemcitabine(G) Carboplatin(C)
Outcome Measures: Progression free survival (PFS);   Overall survival (OS);   Clinical benefit rate (CBR);   The level change of CECs,VEGF,TSP-1,VEGFR,P1GF,MVD in blood.;   adverse reaction;   Time to progression(TTP)

These studies may lead to new treatments and are adding insight into Novoplatinum etiology and treatment.

A major focus of Novoplatinum research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Novoplatinum